 Methods: Randomized, Open-label trial, in parallel groups each of 100 patients. Treatment will be given for 48 weeks positive HCV by polymerase chain reaction PCR patients at 24 weeks will be considered non responders and follow-up for 24 weeks. Total treatment and follow-up duration: 72 weeks. Enrollment duration: 18 months. Total trial duration: 2 years and 9 month, including trial analysis carried out in the 6 months following the follow-up completion of the last patient. Total number of patients: 300. Precision around the expected efficacy rate 45 in intention-to-treat analysis will be 9.6 α 0.05. 